Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index; 14 of the 40 sources its claims cite were checked for support.

APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases

Open access
Perez-Corredor, Paula, Vanderleest, Timothy E., Vacano, Guido N., Sanchez, Justin S., Villalba-Moreno, Nelson D., Marino, Claudia, Krasemann, Susanne, Mendivil-Perez, Miguel A., Aguillón, David, Jiménez-Del-Río, Marlene, Baena, Ana, Sepulveda-Falla, Diego, Lopera, Francisco, Quiroz, Yakeel T., Arboleda-Velasquez, Joseph F., Mazzarino, Randall C. · 2024 · Frontiers in Molecular Neuroscience

Abstract

A patient with the PSEN1 E280A mutation and homozygous for APOE3 Christchurch (APOE3Ch) displayed extreme resistance to Alzheimer’s disease (AD) cognitive decline and tauopathy, despite having a high amyloid burden. To further investigate the differences in biological processes attributed to APOE3Ch, we generated induced pluripotent stem (iPS) cell-derived cerebral organoids from this resistant case and a non-protected control, using CRISPR/Cas9 gene editing to modulate APOE3Ch expression. In the APOE3Ch cerebral organoids, we observed a protective pattern from early tau phosphorylation. ScRNA sequencing revealed regulation of Cadherin and Wnt signaling pathways by APOE3Ch, with immunostaining indicating elevated β-catenin protein levels. Further in vitro reporter assays unexpectedly demonstrated that ApoE3Ch functions as a Wnt3a signaling enhancer. This work uncovered a neomorphic molecular mechanism of protection of ApoE3 Christchurch, which may serve as the foundation for the future development of protected case-inspired therapeutics targeting AD and tauopathies.

Overview

CoChat Summary

TL;DR

In iPS cell-derived cerebral organoids from a PSEN1 E280A APOE3 Christchurch homozygous protected case and a non-protected control, APOE3Ch was associated with reduced early pTau S396 and increased β-catenin/Wnt/Cadherin signaling. ApoE3Ch unexpectedly enhanced Wnt3a reporter signaling, suggesting a neomorphic protective mechanism.

Key findings

  • APOE3Ch cerebral organoids showed a protective pattern of early tau phosphorylation: pTau S396 was reduced, and removal of APOE3Ch increased pTau S396; effects were independent of PSEN1 genotype. Quantification used 3–4 organoids per line, with n = 31–159 measurements for patient α and n = 25–47 for patient ω.
  • scRNA-seq, downsampled to 6,400 cells per dataset, implicated Wnt and Cadherin signaling; APOE3Ch drastically decreased transcript levels of WNT2B, WNT4, and WNT7B but did not influence β-catenin transcript.
  • β-catenin was significantly increased in APOE3Ch organoid rosette body and ribbon. In postmortem patient α brain, nuclear β-catenin colocalization was significantly higher in frontal cortex than hippocampus and occipital cortex (p < 0.0001 for both), while neuronal β-catenin colocalization differed only between hippocampus and occipital cortex (p = 0.025).
  • In a TCF/LEF Wnt reporter assay, ApoE3Ch alone did not induce Wnt signaling, but when combined with Wnt3a it acted as a Wnt signaling activator, whereas ApoE3WT functioned as a Wnt signaling inhibitor; a repeated experiment confirmed a dose-dependent relationship.

Methods

  • Two Paisa kindred women were studied: Patient α was the APOE3Ch homozygous protected case who developed MCI in her seventies; Patient ω was an APOE3WT PSEN1 E280A non-protected control who developed MCI and dementia in her forties. Blood cells were reprogrammed to iPS cells and CRISPR/Cas9-edited to add or remove APOE3Ch and PSEN1 E280A, generating eight cell lines; cerebral organoids were analyzed 29 days after EB spheroid formation.
  • scRNA-seq was performed on six pooled organoids per cell line using 10X Genomics; data were processed with Seurat, SCTransform, Harmony, DoubletFinder, PANTHER, GSEA, SCSA, and Monocle. Immunostaining was quantified in MATLAB, and Wnt signaling was tested in HEK293 TCF/LEF luciferase reporter cells with LiCl, recombinant ApoE proteins, and Wnt3a, using one-way ANOVA with Tukey’s post-hoc test.

Limitations

  • Stated: further studies with more mature organoids are needed to confirm that the protective tau phosphorylation pattern persists over time; Wnt validation relied only on the HEK293 system; CRISPR off-target effects cannot be ruled out despite isogenic controls; developmental patterns of tau phosphorylation may confound results; and cluster cell identification is limited by continuous gene expression patterns.
  • Stated/evident: genetic imputation of causality was not feasible because only a single APOE3Ch homozygote resistant case had been identified, and the study used a small number of patients and cell lines.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fnmol.2024.1373568

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Autosomal dominant Alzheimer’s disease (ADAD) patient in vivo neuroimaging. Patient ω is a non-protected, Paisa kindred control patient and was scanned for amyloid β (A) and tau burden (C). Patient α is an AD-protected Paisa kindred patient and was previously described and scanned for amyloid β (B) and tau burden (D) (Arboleda-Velasquez et al., 2019). Scans indicated elevated amyloid β burden in patient α (B) compared to patient ω (A). Tau burden was elevated in patient ω (C) over patient α (D), with a marked increase in medial temporal and parietal regions. PiB, Pittsburgh Compound B; FTP, Flortaucipir; DVR, Distribution volume ratio; and SUVR, Standardized uptake value ratio.
Figure 1 Autosomal dominant Alzheimer’s disease (ADAD) patient in vivo neuroimaging. Patient ω is a non-protected, Paisa kindred control patient and was scanned for amyloid β (A) and tau burden (C). Patient α is an AD-protected Paisa kindred patient and was previously described and scanned for amyloid β (B) and tau burden (D) (Arboleda-Velasquez et al., 2019). Scans indicated elevated amyloid β burden in patient α (B) compared to patient ω (A). Tau burden was elevated in patient ω (C) over patient α (D), with a marked increase in medial temporal and parietal regions. PiB, Pittsburgh Compound B; FTP, Flortaucipir; DVR, Distribution volume ratio; and SUVR, Standardized uptake value ratio.CC BY · PubMed Central
Figure 2 APOE3Ch decreases pTau S396. Cerebral organoids were formed and stained for nuclei and pTau S396 and imaged at 63X. Representative images from patient ω. (A) and patient α (C) depicted, scale bars = 50 μm. pTau S396 signal intensity was measured, and isogenic controls for each individual patient were averaged together (B,D). Quantification was performed on three to four organoids per line with n = 31–159 measurements for patient α and n = 25–47 measurements for patient ω.
Figure 2 APOE3Ch decreases pTau S396. Cerebral organoids were formed and stained for nuclei and pTau S396 and imaged at 63X. Representative images from patient ω. (A) and patient α (C) depicted, scale bars = 50 μm. pTau S396 signal intensity was measured, and isogenic controls for each individual patient were averaged together (B,D). Quantification was performed on three to four organoids per line with n = 31–159 measurements for patient α and n = 25–47 measurements for patient ω.CC BY · PubMed Central
Figure 3 Cell line scRNA-seq UMAP cluster characteristics. scRNAseq data were downsampled and integrated using SCTransform and Harmony. Individual cell line UMAPs show an overlap, indicating that integration was successful (A). Cell cluster transcript lists were run through GSEA C8 Cell Type for cluster identity (B). * represents cell cluster identities defined by the second highest hit in GSEA C8 Cell Type analysis and the post hoc transcript expression profile, while ** represents cell cluster identities defined by post hoc transcript expression profiles. Similar cluster identities were combined to form reference groups for downstream analysis (C). Asterisk denotes cell cluster identity that was second hit in fGSEA due to its better representation of transcriptomic profile and differentiation protocol used (B,C). Pseudotime was performed using the Monocle analysis suite to represent the differentiation timing to cell identity, initiating the analysis at Cluster 9 (Progenitor) as time zero (D). PANTHER pathways analysis was performed on total cells, all clusters (E), neuronal clusters 0, 1, 8, 10, 12, 13, and 14 (F), and glia-type clusters 3, 5, and 7 (G).
Figure 3 Cell line scRNA-seq UMAP cluster characteristics. scRNAseq data were downsampled and integrated using SCTransform and Harmony. Individual cell line UMAPs show an overlap, indicating that integration was successful (A). Cell cluster transcript lists were run through GSEA C8 Cell Type for cluster identity (B). * represents cell cluster identities defined by the second highest hit in GSEA C8 Cell Type analysis and the post hoc transcript expression profile, while ** represents cell cluster identities defined by post hoc transcript expression profiles. Similar cluster identities were combined to form reference groups for downstream analysis (C). Asterisk denotes cell cluster identity that was second hit in fGSEA due to its better representation of transcriptomic profile and differentiation protocol used (B,C). Pseudotime was performed using the Monocle analysis suite to represent the differentiation timing to cell identity, initiating the analysis at Cluster 9 (Progenitor) as time zero (D). PANTHER pathways analysis was performed on total cells, all clusters (E), neuronal clusters 0, 1, 8, 10, 12, 13, and 14 (F), and glia-type clusters 3, 5, and 7 (G).CC BY · PubMed Central
Figure 4 APOE3Ch influences reelin, β-catenin, and neural rosette features. Immunofluorescence staining was performed on cerebral organoids to identify changes in protein of interest and physical data. Organoids were imaged at 63X and quantified. Representative images of patient ω (A) and patient α (C) stained for reelin and nuclei. Reelin channel intensity was averaged, with isogenic controls averaged together for patient ω (n = 28–64 measurements per line) (B) and patient α (n = 44–120 measurements per line) (D) using three to four organoids per line. Cerebral organoids were stained for β-catenin using three to four organoids per line rosettes and were identified in patient ω (n = 17–29 measurements per line) and imaged at 63X (E). Segmentation was performed, and regions of interest were defined (F). β-catenin was quantified for both rosette body (G) and rosette ribbon (H). Rosette physical features were then measured for area (I) and aspect ratio (J). Scale bars for panels A, C, and E=50 μm.
Figure 4 APOE3Ch influences reelin, β-catenin, and neural rosette features. Immunofluorescence staining was performed on cerebral organoids to identify changes in protein of interest and physical data. Organoids were imaged at 63X and quantified. Representative images of patient ω (A) and patient α (C) stained for reelin and nuclei. Reelin channel intensity was averaged, with isogenic controls averaged together for patient ω (n = 28–64 measurements per line) (B) and patient α (n = 44–120 measurements per line) (D) using three to four organoids per line. Cerebral organoids were stained for β-catenin using three to four organoids per line rosettes and were identified in patient ω (n = 17–29 measurements per line) and imaged at 63X (E). Segmentation was performed, and regions of interest were defined (F). β-catenin was quantified for both rosette body (G) and rosette ribbon (H). Rosette physical features were then measured for area (I) and aspect ratio (J). Scale bars for panels A, C, and E=50 μm.CC BY · PubMed Central
Figure 5 Increased nuclear β-catenin in neurons of protected brain regions of patient α. Representative immunofluorescence (IF) micrographs of the frontal cortex (FC), hippocampus (Hipp), and occipital cortex (OC) stained for β-catenin (red), NeuN (green), and cell nuclei (DAPI, blue). Insets present magnified images of neurons showing the degree of colocalization between the three markers. Scale bar = 100 μm. (A). Bar graphs for colocalization analysis depicting thresholded colocalization volumes (TCVs) between DAPI and β-catenin in FC, Hipp, and OC. The percentage of β-catenin colocalizing in nuclei is significantly higher in FC than in both structures, Hipp and OC (one-way ANOVA, p < 0.0001 for both) (B). Bar graphs for colocalization analysis depicting TCVs between DAPI and β-catenin in FC, Hipp, and OC. The percentage of β-catenin colocalizing with neurons is significantly higher only in Hipp when compared to OC (one-way ANOVA, p = 0.025) (C).
Figure 5 Increased nuclear β-catenin in neurons of protected brain regions of patient α. Representative immunofluorescence (IF) micrographs of the frontal cortex (FC), hippocampus (Hipp), and occipital cortex (OC) stained for β-catenin (red), NeuN (green), and cell nuclei (DAPI, blue). Insets present magnified images of neurons showing the degree of colocalization between the three markers. Scale bar = 100 μm. (A). Bar graphs for colocalization analysis depicting thresholded colocalization volumes (TCVs) between DAPI and β-catenin in FC, Hipp, and OC. The percentage of β-catenin colocalizing in nuclei is significantly higher in FC than in both structures, Hipp and OC (one-way ANOVA, p < 0.0001 for both) (B). Bar graphs for colocalization analysis depicting TCVs between DAPI and β-catenin in FC, Hipp, and OC. The percentage of β-catenin colocalizing with neurons is significantly higher only in Hipp when compared to OC (one-way ANOVA, p = 0.025) (C).CC BY · PubMed Central
Figure 6 ApoE3Ch acts as a Wnt3a signaling enhancer. HEK293 cells with TCF/LEF luciferase reporter element cells were tested against ApoE3 WT, ApoE3Ch, and Wnt3a to assess Wnt signaling activation in triplicate. Cells were treated individually with each compound and in combination (A). Activation was confirmed in a secondary experiment (B). Statistical significance using a one-way ANOVA and post-hoc Tukey’s test to consider a p-value of < 0.05 significance.
Figure 6 ApoE3Ch acts as a Wnt3a signaling enhancer. HEK293 cells with TCF/LEF luciferase reporter element cells were tested against ApoE3 WT, ApoE3Ch, and Wnt3a to assess Wnt signaling activation in triplicate. Cells were treated individually with each compound and in combination (A). Activation was confirmed in a secondary experiment (B). Statistical significance using a one-way ANOVA and post-hoc Tukey’s test to consider a p-value of < 0.05 significance.CC BY · PubMed Central

Verification

Claims the paper makes

10 Valid · 0 Not valid · 16 Not checked · 74 Own results and interpretations

38 more claims

Create a free account to see all 100 claims and to verify the 24 references still open.

See all claims — free account
  • Probably not a substantial claim. 33
  • It may state two separate claims as one. 39

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 54 references

Cited by

See all 28

Metadata

Authors
Perez-Corredor, P., Vanderleest, T. E., Vacano, G. N., Sanchez, J. S., Villalba-Moreno, N. D., Marino, C., Krasemann, S., Mendivil-Perez, M. A., Aguillón, D., Jiménez-Del-Río, M., Baena, A., Sepulveda-Falla, D., Lopera, F., Quiroz, Y. T., Arboleda-Velasquez, J. F., & Mazzarino, R. C.
Affiliations
  • Massachusetts Eye and Ear Infirmary (US)
  • Harvard University (US)
  • University Medical Center Hamburg-Eppendorf (DE)
  • Universidad de Antioquia (CO)
Corresponding author
Mazzarino, Randall C.
Venue
Frontiers in Molecular Neuroscience
Published
2024-03-20
Volume
17
Pages
1373568-1373568
ISSN
1662-5099 (ISSN-L)
OpenAlex
W4393013786
Cited by
28
References
54
Citations by year
2026: 9 · 2025: 11 · 2024: 8
FWCI
7.92
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Molecular Neuroscience (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Institute on Aging (RF1 NS110048)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
Keywords
Alzheimer's disease, PSEN1 E280A mutation, brain organoids, induced pluripotent stem cells, Wnt3a, tau phosphorylation, tauopathy, amyloid burden, CRISPR/Cas9 genome editing, single-cell RNA sequencing, cadherin signaling

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases. https://app.cochat.ai/papers/10.3389/fnmol.2024.1373568
The paper
Perez-Corredor, P., Vanderleest, T. E., Vacano, G. N., Sanchez, J. S., Villalba-Moreno, N. D., Marino, C., Krasemann, S., Mendivil-Perez, M. A., Aguillón, D., Jiménez-Del-Río, M., Baena, A., Sepulveda-Falla, D., Lopera, F., Quiroz, Y. T., Arboleda-Velasquez, J. F., & Mazzarino, R. C. (2024). APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases. Frontiers in Molecular Neuroscience. https://doi.org/10.3389/fnmol.2024.1373568

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.